News

These Stocks Are Moving the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More
Stocks were rising Monday after The Wall Street Journal reported Tehran was looking to resume talks with the White House over ...
Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom
Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...
Sarepta reports second patient death after treatment with Duchenne gene therapy
Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...
STAT1h
After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...
GlobalData on MSN8h
Sarepta and Roche halt DMD gene therapy’s use after second death
Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...
BioSpace8h
Second Patient Dies After Receiving Sarepta’s DMD Gene Therapy Elevidys
Sarepta’s shares crashed 41% in pre-market trading Monday morning to $21.01 after the biotech reported a second death from ...
Managed Healthcare Executive5h
Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients
A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...
Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy
Sarepta Therapeutics, Inc. stock fell after an ELEVIDYS-related death. However, click for why strong SRTP revenue growth and ...